21 patients, aged 1 to 15 years, who developed manifest varicella/zoster-virus infection while on chemotherapy for malignant disease were treated with acyclovir. Drug dosage was 10 mg/kg every eight hours for 5 days as a one hour infusion. The clinical course of the infection in all patients was mild. 1 to 4 (median 2,2) days after beginning of acyclovir therapy the formation of new lesions stopped. Within 4 to 8 (median 5,9) days all vesicles were scabbed . In 13 patients with fever in the beginning the temperature fell within 2 to 6 (median 2,6) days of treatment. The development of visceral involvement was not observed during or after acyclovir therapy. Acyclovir was well tolerated. Tests of the hematopoietic, liver and renal functions before and after acyclovir therapy revealed no adverse effects of the drug. Also the immunologic response seemed not to be impaired. With one exception, all patients investigated had antibodies against varicella/zoster-virus after recovery. In order to prevent varicella infection after household exposure two immunocompetent patients were treated prophylactically with acyclovir tablets (400 mg 5 times a day for 5 days). Both children did not exhibit manifest varicella/zoster infection, but five weeks later they had antibodies against varicella/zoster-virus (KBR 1:10, resp. KBR 1:20).

Download full-text PDF

Source

Publication Analysis

Top Keywords

median days
12
acyclovir therapy
12
antibodies varicella/zoster-virus
8
acyclovir
6
patients
5
days
5
[acyclovir therapy
4
therapy varicella/zoster
4
varicella/zoster diseases
4
diseases immunocompromised
4

Similar Publications

Analysis of time to regulatory approval in an exception from informed consent trial in trauma patients.

J Trauma Acute Care Surg

October 2024

From the Department of Surgery (S.W.S., C.R.C.-L., S.D., T.W.C., M.A.N., J.R., J.B.H., J.O.J.), Center for Injury Science, and Department of Epidemiology (R.L.G.), University of Alabama at Birmingham, Birmingham, Alabama; Avania Clinical (S.G.), Marlborough, Massachusetts; CSL Behring (A.S., J.C., S.R.S., B.G., J.R., J.D.), King of Prussia, Pennsylvania; Office of Institutional Review Board (A.J.M.), University of Alabama at Birmingham, Birmingham, Alabama; Advarra (L.G., A.H.), Columbia, Maryland; and Department of Surgery (B.J.), University of Arizona, Tucson, Arizona.

Background: The interactive media-based approach to community consultation and public disclosure (CC/PD), a key step when conducting exception from informed consent (EFIC) clinical trials, is intended to be completed in 4 months. This analysis characterizes the process, from initiation of CC/PD activities to institutional review board approval, to better understand the barriers and how these can be mitigated.

Methods: This is a retrospective post hoc analysis of data collected as part of the CC/PD campaigns conducted for a large trial involving up to 90 trauma centers in the United States.

View Article and Find Full Text PDF

[Initial experience of minimally invasive liver resection at a reference center in Mexico].

Cir Cir

January 2025

Departamento de Cirugía Hepatopancreatobiliar, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México.

Objective: Minimally invasive liver resection is employed worldwide for the management of benign and malignant liver lesions. There is no description of postoperative outcomes in the Mexican population. This study aims to report the initial experience in Mexico.

View Article and Find Full Text PDF

Purpose: Trastuzumab-pertuzumab (HP) plus taxane is a current standard first-line therapy for recurrent or metastatic human epidermal growth factor 2 (HER2)+ breast cancer (BC). We investigated noninferiority of eribulin to a taxane when combined with dual HER2 blockade as first-line systemic treatment for locally advanced/metastatic HER2+ BC.

Methods: In the phase III EMERALD trial (target sample size, 480; ClinicalTrials.

View Article and Find Full Text PDF

Background: In this study, the preliminary experience of endoscopic nipple-areolar-complex (NAC) sparing total mastectomy were analyzed and reported.

Methods: The medical records of the patients who underwent Endoscopic NAC sparing total mastectomy from November 2019 to June 2022 in a single institute were collected and analyzed. The medical records of their clinicopathologic characteristics, perioperative parameters, postoperative complications, oncologic results were collected retrospectively.

View Article and Find Full Text PDF

Objectives: Despite being a frequent entry point of care, it remains unknown if families' needs are being met across pediatric emergency departments (PEDs). Study objectives were to describe caregivers' perceived overall PED experience and needs and to what extent these needs were met.

Methods: This descriptive, cross-sectional survey with medical record review was conducted in 10 Canadian PEDs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!